Author: Zhichao Feng; Jennifer Li; Shanhu Yao; Qizhi Yu; Wenming Zhou; Xiaowen Mao; Huiling Li; Wendi Kang; Xin Ouyang; Ji Mei; Qiuhua Zeng; Jincai Liu; Xiaoqian Ma; Pengfei Rong; Wei Wang
Title: The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis Document date: 2020_4_10
ID: k65501xp_45
Snippet: in our cohort and relatively small size. Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of coronavirus, which has been confirmed to inhibit SARS-CoV-2 in vitro. [36] [37] [38] A recent open label non randomized clinical trial reported that hydroxychloroquine combined with azithromycin is significantly associated with viral.....
Document: in our cohort and relatively small size. Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of coronavirus, which has been confirmed to inhibit SARS-CoV-2 in vitro. [36] [37] [38] A recent open label non randomized clinical trial reported that hydroxychloroquine combined with azithromycin is significantly associated with viral load reduction/disappearance in COVID-19 patients. 39 Even so, more RCTs to assess the therapeutic effects of chloroquine on COVID-19 need to be conducted.
Search related documents:
Co phrase search for related documents- cellular receptor and coronavirus cellular receptor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
- cellular receptor and open label: 1
- cellular receptor and SARS inhibit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- cellular receptor and therapeutic effect: 1, 2, 3
- cellular receptor and virus cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69
- cellular receptor and virus cell fusion: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- cellular receptor and virus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- cellular receptor and virus infection block: 1
- cellular receptor and vitro SARS inhibit: 1
- chloroquine therapeutic effect and therapeutic effect: 1, 2, 3, 4, 5
- chloroquine therapeutic effect and virus infection: 1
- clinical trial and conduct need: 1, 2
- clinical trial and endosomal increase: 1
- clinical trial and load reduction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- clinical trial and non randomized clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- clinical trial and open label: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clinical trial and open label non randomized clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9
- clinical trial and relatively small size: 1, 2
- clinical trial and SARS inhibit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Co phrase search for related documents, hyperlinks ordered by date